Evidence map›Paper›PMID 42387313›Full record

Trial reportDiabetes, obesity & metabolism2026

Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.

Jiaying Ni, Jingyi Lu, Fei Gao, Min Li, Minlu Zhang, Qin Du, Lei Kang, Danfeng Peng, Jian Zhou

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaying NiDepartment of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.
Jingyi LuDepartment of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.
Fei GaoDepartment of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.ORCID https://orcid.org/0000-0002-0722-2349
Min LiSanofi Investment Co. Ltd., Beijing, China.
Minlu ZhangSanofi Investment Co. Ltd., Shanghai, China.
Qin DuSanofi Investment Co. Ltd., Shanghai, China.
Lei KangSanofi Investment Co. Ltd., Beijing, China.
Danfeng PengDepartment of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.ORCID https://orcid.org/0009-0006-6617-139X
Jian ZhouDepartment of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.ORCID https://orcid.org/0000-0002-1534-2279

Funding

Sanofi
6 · The paper itself

Abstract

aimsTo evaluate the impact of iGlarLixi on the depth of glycaemic control, glycaemic variability (GV) and postprandial glucose (PPG) control versus insulin glargine 100 U/mL (iGlar) or lixisenatide (Lixi) in Asian Pacific individuals with type 2 diabetes (T2D). MATERIALS AND

methodsA post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin (LixiLan-L-CN). Outcomes were evaluated from baseline to end-of-treatment (EOT; Week 24 or 30, respectively). Using self-monitoring of blood glucose (SMBG) profiles, glycaemic control depth was assessed via derived time in tight range (dTITR; 3.9-7.8 mmol/L). GV was evaluated using standard deviation (SD) of SMBG, high blood glucose index (HBGI), mean absolute glucose (MAG), and mean amplitude of glycaemic excursions (MAGE). PPG at 0.5, 1, and 2 h was measured via standardised meal tests.

resultsFrom baseline to EOT, iGlarLixi provided greater increases in dTITR versus iGlar (least squares mean difference 15.03%) or Lixi (29.14%) in LixiLan-O-AP, and versus iGlar (15.93%) in LixiLan-L-CN. At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan-O-AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan-L-CN. iGlarLixi provided generally greater reductions in SD of SMBG, HBGI, MAG, MAGE and 0.5-, 1- and 2-h PPG versus iGlar or Lixi and greater 2-h PPG < 10.0 mmol/L achievement rates at EOT.

conclusioniGlarLixi improves dTITR, GV, and PPG control versus iGlar or Lixi in Asian Pacific individuals with T2D.

Indexed as

Diabetes Mellitus, Type 2Glycemic ControlHypoglycemic AgentsInsulin GlarginePeptidesAgedBlood GlucoseBlood Glucose Self-MonitoringEast Asian PeopleFemaleGlucagon-Like Peptide 1Glucagon-Like Peptide-2 ReceptorGlycated HemoglobinHumansMaleMiddle AgedBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like Peptide-2 ReceptorGlycated HemoglobinHypoglycemic AgentsInsulin GlarginelixisenatidePeptidesglycaemic controliGlarLixiinsulin glarginelixisenatidetype 2 diabetes

Identifiers

PMID42387313
PMCPMC13449076

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.